Japanese encephalitis virus: A multi-epitope loaded peptide vaccine formulation using reverse vaccinology approach

Chakraborty, Supriyo; Barman, Antara; Deb, Bornali

doi:10.1016/j.meegid.2019.104106

Cited by 10 publications

(6 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, a study used a combination of immune T-cell and B-cell epitope predictions with molecular docking simulations to design a potential epitope-based peptide vaccine that would trigger a host immune response against the Chikungunya virus [ 181 ]. Similar work has been performed by Chakraborty et al [ 182 ], where a multi-epitope loaded peptide vaccination was designed against the Japanese encephalitis virus (JEV) by reverse vaccinology and in silico study of B and T-cells against five JEV proteins (viz. E, prM, NS1, NS3 and NS5).…”

Section: Covid-19 Control Measuresmentioning

confidence: 90%

COVID-19: A Review on the Novel Coronavirus Disease Evolution, Transmission, Detection, Control and Prevention

Sharma

Farouk

Lal

2021

Viruses

530

291

View full text Add to dashboard Cite

Three major outbreaks of the coronavirus, a zoonotic virus known to cause respiratory disease, have been reported since 2002, including SARS-CoV, MERS-CoV and the most recent 2019-nCoV, or more recently known as SARS-CoV-2. Bats are known to be the primary animal reservoir for coronaviruses. However, in the past few decades, the virus has been able to mutate and adapt to infect humans, resulting in an animal-to-human species barrier jump. The emergence of a novel coronavirus poses a serious global public health threat and possibly carries the potential of causing a major pandemic outbreak in the naïve human population. The recent outbreak of COVID-19, the disease caused by SARS-CoV-2, in Wuhan, Hubei Province, China has infected over 36.5 million individuals and claimed over one million lives worldwide, as of 8 October 2020. The novel virus is rapidly spreading across China and has been transmitted to 213 other countries/territories across the globe. Researchers have reported that the virus is constantly evolving and spreading through asymptomatic carriers, further suggesting a high global health threat. To this end, current up-to-date information on the coronavirus evolution and SARS-CoV-2 modes of transmission, detection techniques and current control and prevention strategies are summarized in this review.

show abstract

Section: Covid-19 Control Measuresmentioning

confidence: 90%

COVID-19: A Review on the Novel Coronavirus Disease Evolution, Transmission, Detection, Control and Prevention

Sharma

Farouk

Lal

2021

Viruses

530

291

View full text Add to dashboard Cite

show abstract

“…JE occurs predominantly in the countries of Asia-Pacific region. Recently, there are shreds of evidences that birds and pigs were infected with JEV in Europe which were long considered free of JEV infection [3,4].…”

Section: Introductionmentioning

confidence: 99%

Novel Japanese encephalitis virus NS1-based vaccine: Truncated NS1 fused with E. coli heat labile enterotoxin B subunit

et al. 2021

View full text Add to dashboard Cite

Background: Current vaccines against Japanese encephalitis virus (JEV) of flaviviruses have some disadvantages, such as the risk of virulent reversion. Non-structural protein NS1 is conserved among flaviviruses and confers immune protection without the risk of antibody-dependent enhancement (ADE). Therefore, NS1 has become a promising vaccine candidate against flaviviruses. Methods: A NS1-based vaccine (LTB-NS1 Δ63 ) with a truncated NS1 protein (NS1 Δ63 ) fused to E. coli heat-labile enterotoxin B subunit (LTB) was expressed in E.coli and explored for its ability to induce immune responses. Safety of LTB-NS1 Δ63 was assessed by determining its toxicity in vitro and in vivo. Protective capability of LTB-NS1 Δ63 and its-induced antisera was evaluated in the mice challenged with JEV by analyzing mortality and morbidity. Findings: LTB-NS1 Δ63 induced immune responses to a similar level as LTB-NS1, but more robust than NS1 Δ63 alone, particularly in the context of oral immunization of mice. Oral vaccination of LTB-NS1 Δ63 led to a higher survival rate than that of NS1 Δ63 or live-attenuated JEV vaccine SA14À14À2 in the mice receiving lethal JEV challenge. LTB-NS1 Δ63 protein also significantly decreases the morbidity of JEV-infected mice. In addition, passive transfer of LTB-NS1 Δ63 -induced antisera provides a protection against JEV infection in mice. Interpretation: NS1 Δ63 bears JEV NS1 antigenicity. Besides, LTB-NS1 Δ63 could serve as a novel protein-based mucosa vaccine targeting JEV and other flaviviruses.

show abstract

“…These types of policies may help to reduce the risk of infection in healthy people and should be adopted by other countries that are geographically close to JEV-endemic countries but are not themselves affected by JEV. Recently, using reverse vaccinology and in silico approaches, Chakraborty et al designed a peptide vaccine loaded with multiple epitopes belonging to the E, prM, NS1, NS3, and NS5 proteins of JEV [ 160 ]. This peptide vaccine is being studied through in vivo and in vitro experiments and still needs to be tested in clinical trials to examine its immunogenicity and efficacy.…”

Section: Recent Insights and Developments: Vaccines Therapeutics And ...mentioning

confidence: 99%

Molecular pathogenesis of Japanese encephalitis and possible therapeutic strategies

et al. 2022

View full text Add to dashboard Cite

Japanese encephalitis virus (JEV), a single-stranded, enveloped RNA virus, is a health concern across Asian countries, associated with severe neurological disorders, especially in children. Primarily, pigs, bats, and birds are the natural hosts for JEV, but humans are infected incidentally. JEV requires a few host proteins for its entry and replication inside the mammalian host cell. The endoplasmic reticulum (ER) plays a significant role in JEV genome replication and assembly. During this process, the ER undergoes stress due to its remodelling and accumulation of viral particles and unfolded proteins, leading to an unfolded protein response (UPR). Here, we review the overall strategy used by JEV to infect the host cell and various cytopathic effects caused by JEV infection. We also highlight the role of JEV structural proteins (SPs) and non-structural proteins (NSPs) at various stages of the JEV life cycle that are involved in up- and downregulation of different host proteins and are potentially relevant for developing efficient therapeutic drugs. Graphical abstract

show abstract

Japanese encephalitis virus: A multi-epitope loaded peptide vaccine formulation using reverse vaccinology approach

Cited by 10 publications

References 52 publications

COVID-19: A Review on the Novel Coronavirus Disease Evolution, Transmission, Detection, Control and Prevention

COVID-19: A Review on the Novel Coronavirus Disease Evolution, Transmission, Detection, Control and Prevention

Novel Japanese encephalitis virus NS1-based vaccine: Truncated NS1 fused with E. coli heat labile enterotoxin B subunit

Molecular pathogenesis of Japanese encephalitis and possible therapeutic strategies

Contact Info

Product

Resources

About